iSpecimen Inc. (ISPC) 株式分析

企業概要

iSpecimen Inc. is a specialized operator of a marketplace designed to connect medical researchers requiring access to specific subjects, samples, and data with hospitals and laboratories globally. This enterprise functions within the Healthcare sector, specifically focusing on the Diagnostics & Research industry, where it facilitates the flow of biospecimens essential for life science advancement. The company's current market capitalization stands at 3,860,000 米ドル (3.86M), while its trailing twelve-month revenue totals 1,930,000 米ドル (1.93M) and its workforce consists of 7 名 (7 employees). These valuation and revenue figures indicate that the company operates on a micro-cap scale with limited operational breadth, reflecting a niche business model that relies heavily on proprietary platform usage rather than broad commercial scale or extensive physical infrastructure.

財務健全性

The company reported trailing twelve-month revenue of 1,930,000 米ドル (1.93M) alongside a net income loss of 10,487,532 米ドル (-10,487,532) and an EBITDA of -8,717,890 米ドル (-8,717,890). The significant disparity between the modest revenue figure and the substantial net income deficit reveals a cost structure characterized by high operating expenses that far exceed current sales generation. Free cash flow for the period was -2,782,585 米ドル (-2,782,585), indicating that the company is currently consuming cash reserves to fund its operations and development efforts rather than generating surplus liquidity. Analysis of the profit margins shows a gross margin of 1.2%, an operating margin of -5,192.9%, and a profit margin of 0.0%, suggesting that the company struggles to cover its direct costs and overhead expenses effectively at its current volume. On the balance sheet, the company holds cash assets of 6,880,000 米ドル (6.88M) against total debt of 268,798 米ドル (268,798), resulting in a debt-to-equity ratio of 8.70 which technically indicates high leverage but is mitigated by the significant cash cushion. The current ratio stands at 1.12, suggesting that the company possesses just sufficient current assets to cover its short-term liabilities, leaving little room for error in liquidity management. Furthermore, the return on equity is -327.8% and the return on assets is -59.4%, metrics that reveal the current inability of management to generate positive returns on the capital invested or the assets held by the firm.

バリュエーション評価

The trailing twelve-month P/E ratio is listed as not available (N/A) due to negative earnings, while the forward P/E is reported as -0.16, a metric that implies the market is pricing in future earnings recovery or continued losses depending on the projection model used. The price-to-book ratio is 0.41, indicating that the company's market valuation is trading at less than half of its book value, which often suggests the market assigns low value to the firm's intangible assets or anticipates challenges in converting assets to cash. Alternative valuation metrics include a price-to-sales ratio of 2.00 and an EV/EBITDA of 0.32; these figures suggest the market values the company primarily based on its revenue stream given the lack of profitability, rather than earnings power. The stock's 52-week price range spans from a low of 0.13 米ドル (0.13) to a high of 3.18 米ドル (3.18), and the current trading price sits significantly below the 52-week high, reflecting the volatility and recent underperformance relative to the asset's peak valuation. The beta coefficient is 1.98, which indicates that the share price is highly volatile and tends to fluctuate with nearly double the intensity of the broader market movements.

Growth & Income

The revenue growth year-over-year declined by 96.5% (-96.5%), while earnings growth is not applicable (N/A) due to the reported net loss, implying that the company is in a contractionary phase regarding top-line sales rather than an expansionary growth stage. The company does not distribute dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings, or in this case, the capital base, are theoretically reinvested into the business or used to cover losses rather than returned to shareholders. The overall growth and income profile presents a challenging picture characterized by severe revenue contraction, negative cash generation, and an absence of dividend income, which limits the investment thesis to potential turnaround scenarios based on future operational improvements.